ClinicalTrials.gg
RecruitingNCT06865638Updated Mar 31, 2026

Efficacy and Safety of Colorectal Anastomotic Leak Testing

An interventional study of Intraoperative leak testing in Colorectal Cancer, Leakage Testing and Colorectal Surgery, sponsored by Nanchong Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Nanchong Central Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,139 studies in Colorectal Neoplasms with a site in China — 529 open to participants now, 606 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
191st of 894
264 · median 80
Started
2024
with 156 others
No phase
150 of 1,139
81 open now
Primary completion
2029-01
later than 552 of 605 live
Registered
877th of 1,139
by date

Among the 1,139 studies in Colorectal Neoplasms with a site in China, this one is the 191st largest by planned enrollment of the 894 interventional ones that give a count, is one of 157 that started in 2024, is one of 150 with no phase, reaches primary completion later than 552 of the 605 other live ones, and was the 877th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

529 of the 1,139 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

524 more — sign in →

All 529 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,139 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

To evaluate the effectiveness of the gastroscopy, air, and methylene blue (GAM) leak testing in reducing the incidence of postoperative anastomotic complications, especially anastomotic leakage, in patients with colorectal cancer. The primary outcomes included is the incidence of anastomotic complications (mainly anastomotic leak) within 30 days after surgery

03

Conditions studied

  • Colorectal Cancer
  • Leakage Testing
  • Colorectal Surgery
  • Complications
  • Anastomotic Leakage
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with colorectal cancer by pathology and scheduled for surgical treatment who meet the surgical indications.
  2. Aged between 18 and 85 years.
  3. (ASA) physical status classification is I - III.
  4. The patient or his/her legal representative can understand and sign the form and is willing to cooperate throughout the study process.

Exclusion criteria

Exclusion Criteria:

  1. Patients with preoperatively diagnosed anastomotic leak or other severe abdominal infections.
  2. Patients with severe cardiovascular and cerebrovascular diseases (such as recent myocardial infarction, unstable angina pectoris, severe heart failure, acute cerebral infarction, etc.) who cannot tolerate surgery and related tests.
  3. Patients with severely impaired liver and kidney function (liver function Child - Pugh classification C or above, rate \< 30 ml/min).
  4. Patients with coagulation disorders (such as count \< 50×10⁹/L, (INR) > 1.5, etc.) that cannot be corrected or are receiving anticoagulant therapy that cannot be adjusted.
  5. Patients with a history of abdominal radiotherapy or multiple abdominal surgeries and severe abdominal adhesions that may affect the operation and detection procedures.
  6. Patients with other malignant tumors who are receiving active anti-tumor treatment such as radiotherapy and chemotherapy.
  7. Patients with mental illness or cognitive impairment who cannot cooperate with the study process and follow-up.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
264 participants (estimated)

Study arms

  • Experimental
    ≤5cm Rectal, Pre-chemo, Leak Test

    Patients with rectal cancer ≤ 5 cm from the anus, received preoperative chemotherapy and intraoperative leak testing.

    Procedure: Intraoperative leak testing

  • No intervention
    ≤5cm Rectal, Pre-chemo, No Leak Test

    Patients with rectal cancer ≤ 5 cm from the anus, received preoperative chemotherapy, and had no intraoperative leak testing.

  • Experimental
    ≤5cm Rectal, No pre-chemo, Leak Test

    Patients with rectal cancer ≤ 5 cm from the anus, didn't receive preoperative chemotherapy, and underwent intraoperative leak testing.

    Procedure: Intraoperative leak testing

  • No intervention
    ≤5cm Rectal, No pre-chemo, No Leak Test

    Patients with rectal cancer ≤ 5 cm from the anus, didn't receive preoperative chemotherapy, and had no intraoperative leak testing.

  • Experimental
    >5cm Colorectal, Pre-chemo, Leak Test

    Patients with colorectal cancer \> 5 cm from the anus, received preoperative chemotherapy, and underwent intraoperative leak testing.

    Procedure: Intraoperative leak testing

  • No intervention
    >5cm Colorectal, Pre-chemo, No Leak Test

    Patients with colorectal cancer \> 5 cm from the anus, received preoperative chemotherapy, and had no intraoperative leak testing.

  • Experimental
    >5cm Colorectal, No pre-chemo, Leak Test

    Patients with colorectal cancer \> 5 cm from the anus, didn't receive preoperative chemotherapy, and underwent intraoperative leak testing.

    Procedure: Intraoperative leak testing

  • No intervention
    >5cm Colorectal, No pre-chemo, No Leak Test

    Patients with colorectal cancer \> 5 cm from the anus, didn't receive preoperative chemotherapy, and had no intraoperative leak testing.

Interventions

  • ProcedureIntraoperative leak testing

    ◦After anastomosis was completed, the integrity of anastomosis was tested intraoperatively. The methods include directly observing the integrity of the anastomosis under gastroscopy, immersing the anastomosis in 500 - 1000 mL of warm saline and temporarily occluding the distal end, filling the anastomotic bowel with air, and injecting 60 mL of methylene blue through colonoscopy. Wrapping a white gauze pad around the anastomosis and observing for methylene blue leakage.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Anastomotic Leak within 30 days

    Count the number of participants who develop anastomotic leak within 30 days after colorectal cancer surgery.

    Time frame: 30 days

Secondary outcomes

  1. Number of Participants with Postoperative Complications within 30 days

    Count the number of participants who develop postoperative bleeding, anastomotic stenosis, and intra-abdominal infection within 30 days after colorectal cancer surgery.

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jan 2029, 49 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 49 months is above that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 10, 2025
StartActual
Dec 22, 2024
Primary completionEst.
Jan 31, 2029
CompletionEst.
Apr 1, 2029
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06865638
Lead sponsor
Nanchong Central Hospital
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Dec 22, 2024
Primary completion
Jan 31, 2029 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
Mar 31, 2026

Study contacts

Yunhong Tian, doctor
Contact
drtianyunhong@126.com
13508087719

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion